This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wheeler, G. P. Articles by Briggs, S. D. Search for Related Content PubMed PubMed Citation Articles by Wheeler, G. P. Articles by Briggs, S. D.

Searches for Exploitable Biochemical Differences between Normal and Cancer Cells

X. Catabolism of Purines by Regressing Tumors^*

( Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama)

The in vitro anabolism and catabolism of radioactive purines by minces and of radioactive purines and purine ribonucleotides by sonicates of growing and regressing tumors were investigated with the aid of paper chromatography, radioautography, and radioassay. Two systems of growing and regressing tumors were used: (a) cyclophos-phamide-sensitive and cyclophosphamide-resistant plasmacytomas growing bilaterally in hamsters that were subsequently treated in vivo with cyclophosphamide,¹ (b) mammary tumors induced in rats with 7,12-dimethylbenzanthracene, with subsequent surgery or treatment of the rats consisting of hypophysectomy, administration of testosterone, ovariectomy, or ovariectomy plus administration of diethylstilbestrol. More catabolism and apparently less anabolism of purines and purine ribonucleotides occurred with preparations of regressing tumors than with preparations of growing tumors. The significance of these results is discussed.

^* This work was supported by the Cancer Chemotherapy National Service Center, National Cancer Institute, under National Institutes of Health Contract Nos. SA-43-ph-2433, SA-43-ph-4358, and SA-43-ph-3784; and by grants from the Charles F. Kettering Foundation and the Alfred P. Sloan Foundation.

¹ Cyclophosphamide is 2-[bis(2-chloroethyl)amino]-2H-1,3,2-oxazaphosphorinane 2-oxide.

Affiliated with Sloan-Kettering Institute for Cancer Research, New York, N.Y.

Received 6/18/62.